Compare GORO & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GORO | ICCC |
|---|---|---|
| Founded | 1998 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.9M | 55.5M |
| IPO Year | 2010 | 1995 |
| Metric | GORO | ICCC |
|---|---|---|
| Price | $1.53 | $6.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.75 | N/A |
| AVG Volume (30 Days) | ★ 3.2M | 12.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.33 |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $65,726,000.00 | $26,493,169.00 |
| Revenue This Year | $9.04 | N/A |
| Revenue Next Year | $93.07 | N/A |
| P/E Ratio | ★ N/A | $32.67 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $0.34 | $4.32 |
| 52 Week High | $1.87 | $7.60 |
| Indicator | GORO | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 51.86 | 53.42 |
| Support Level | $0.79 | $5.72 |
| Resistance Level | $1.81 | $6.91 |
| Average True Range (ATR) | 0.12 | 0.23 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 38.90 | 57.43 |
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.